HCV and autoimmunity

Current Pharmaceutical Design

Volumn 14, Issue 17, 2008, Pages 1678-1685

  Ferri, S ^a,b   Muratori, L ^b   Lenzi, M ^b   Granito, A ^b   Bianchi, F B ^b   Vergani, Diego ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiviral therapy; Hepatitis C virus; Immune system dysregulation; Molecular mimicry

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; AUTOANTIBODY; CD19 ANTIGEN; CD20 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CYTOCHROME P450 2D6; CYTOKINE; HLA A1 ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERFERON; NON ORGAN SPECIFIC AUTOANTIBODY; TUMOR NECROSIS FACTOR; VIRUS ENVELOPE PROTEIN;

ANTIBODY PRODUCTION; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; B LYMPHOCYTE; CELL INVASION; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; GENETIC PREDISPOSITION; HEPATITIS C; HLA SYSTEM; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOPATHOGENESIS; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; VIRUS VIRULENCE;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C; HISTOCOMPATIBILITY ANTIGENS; HUMANS; T-LYMPHOCYTES;

EID: 47349098609     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784746824     Document Type: Review

References (119)

1. Bottazzo GF, Florin-Christensen A, Fairfax A, Swana G, Doniach D, Groeschel-Stewart U. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 1976; 29: 403-10.
2. Cassani F, Bianchi FB, Lenzi M, Volta U, Pisi E. Immunomorphological characterisation of antinuclear antibodies in chronic liver disease. J Clin Pathol 1985; 38: 801-5.
3. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, et al. Serum autoantibodies in chronic hepatitis C: Comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26: 561-6.
4. Dickson RC. Clinical manifestations of hepatitis C. Clin Liver Dis 1997; 1: 569-85.
5. Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: A nested case-control study of the Dionysos cohort. Gut 1999; 45:435-41.
6. Monti V, Aghemo A, Rumi MG, Donato MF, Del Ninno E, Colombo M. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies. Antivir Ther 2005; 10: 715-20.
7. Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR, Manns MP, et al. Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-83.
8. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid 2006; 16: 563-72.
9. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974; 57: 775-88.
10. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTI-VIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42: 2204-12.
11. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-5.
12. Nieters A, Kallinowski B, Brennan P, Ott M, Maynadie M, Benavente Y, et al. Hepatitis C and risk of lymphoma: Results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006; 131: 1879-86.
13. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: Systematic review and meta-analysis. Gastroenterology 2003; 125: 1723-32.
14. Monti G, Pioltelli P, Saccardo F, Campanini M, Candela M, Cavallero G, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005; 165: 101-5.
15. Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis C-associated mixed cryoglobulinaemia: A crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 2007; 46: 1234-42.
16. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 1995; 108: 157-64.
17. Hwang SJ, Chu CW, Huang DF, Lan KH, Chang FY, Lee SD. Genetic predispositions for the presence of cryoglobulinemia and serum autoantibodies in Chinese patients with chronic hepatitis C. Tissue Antigens 2002; 59: 31-7.
18. Jurado A, Cardaba B, Jara P, Cuadrado P, Hierro L, de Andres B, et al. Autoimmune hepatitis type 2 and hepatitis C virus infection: study of HLA antigens. J Hepatol 1997; 26: 983-91.
19. Muratori P, Czaja AJ, Muratori L, Pappas G, Maccariello S, Cassani F, et al. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol 2005; 11: 1862-6.
20. Muratori P, Czaja AJ, Muratori L, Granito A, Guidi M, Ferri S, et al. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci 2007; 52: 179-84.
21. Invernizzi P, Battezzati PM, Crosignani A, Perego F, Poli F, Morabito A, et al. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J Hepatol 2003; 38: 401-6.
22. Lenzi M, Frisoni M, Mantovani V, Ricci P, Muratori L, Francesconi R, et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 1998; 91: 2062-6.
23. Amoroso A, Berrino M, Canale L, Cornaglia M, Guarrera S, Mazzola G, et al. Are HLA class II and immunoglobulin constant region genes involved in the pathogenesis of mixed cryoglobulinemia type II after hepatitis C virus infection? J Hepatol 1998; 29: 36-44.
24. Cacoub P, Renou C, Kerr G, Hue S, Rosenthal E, Cohen P, et al. Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum 2001; 44: 2118-24.
25. Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: Spontaneous viral clearance and chronic HCV infection. Gut 2001; 49: 423-30.
26. Lopez-Vazquez A, Rodrigo L, Mina-Blanco A, Martinez-Borra J, Fuentes D, Rodriguez M, et al. Extended human leukocyte antigen haplotype EH18.1 influences progression to hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 2004; 189: 957-63.
27. Renou C, Halfon P, Pol S, Cacoub P, Jouve E, Bronowicki JP, et al. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransfemse levels. Gut 2002; 51: 585-90.
28. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354: 2119-24.
29. Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: A prospective controlled study. Clin Endocrinol (Oxf) 1999; 50: 503-9.
30. Shevach EM. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002; 2: 389-400.
31. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4[+]CD25[+] regulatory T-cells in autoimmune liver disease. J Hepatol 2004; 41: 31-7.
32. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HP, Liu C, et al. An immunomodulatory role for CD4[+]CD25[+] regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40: 1062-71.
33. Perrella A, Vitiello L, Atripaldi L, Conti P, Sbreglia C, Altamura S, et al. Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution. Gut 2006; 55: 1370-1.
34. Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P, et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 2005; 79: 7852-9.
35. Boyer O, Saadoun D, Abriol J, Dodille M, Piette JC, Cacoub P, et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004; 103: 3428-30.
36. Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 2005; 204: 43-54.
37. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.
38. Migita K, Abiru S, Maeda Y, Nakamura M, Komori A, Ito M, et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 200; 68: 586-91.
39. Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, et al. Elevated serum B-Lymphocyte activating factor [BAFF] in chronic hepatitis C virus infection: Association with autoimmunity. J Autoimmun 2006; 27: 134-9.
40. Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol 2005; 5: 136-48.
41. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 1996; 271: 348-50.
42. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 2000; 18: 393-422.
43. Carter RH, Fearon DT. CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992; 256: 105-7.
44. Tooze RM, Doody GM, Fearon DT. Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Immunity 1997; 7: 59-67.
45. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 2002; 8: 373-8.
46. Mehlhop E, Whitby K, Oliphant T, Marri A, Engle M, Diamond MS. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol 2005; 79: 7466-77
47. Lyubchenko T, Dal Porto JM, Holers VM, Cambier JC. Cutting edge: Complement [C3d]-linked antigens break B cell anergy. J Immunol 2007; 179: 2695-9.
48. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
49. Rosa D, Saletti G, De. Gregorio E, Zorat F, Coma C, D'Oro U, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005; 102: 18544-9.
50. Wack A, Soldaini E, Tseng C, Nuti S, Klimpel G, Abrignani S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol 2001; 31: 166-75.
51. Weng WK, Levy S. Hepatitis C virus [HCV] and lymphomagenesis. Leuk Lymphoma 2003; 44: 1113-20.
52. Crotta S, Stilla, A, Wack A, D'Andrea A, Nuti S, D'Oro U, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195: 35-41
53. Deng J, Dekruyff RH, Freeman GJ, Umetsu DT, Levy S. Critical role of CD81 in cognate T-B cell interactions leading to Th2 responses. Int Immunol 2002; 14: 513-23.
54. Takyar ST, Li D, Wang Y, Trowbridge R, Gowans EJ. Specific detection of minus-strand hepatitis C virus RNA by reverse-transcription polymerase chain reaction on PolyA[+]-purified RNA. Hepatology 2000; 32: 382-7.
55. Pal S, Sullivan DG, Kim S, Lai KK, Kae J, Cotler SJ, et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: Implications of HCV lymphotropism. Gastroenterology 2006; 130: 1107-16.
56. Muratori L, Gibellini D, Lenzi M, Cataleta M, Muratori P, Morelli MC, et al. Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood 1996; 88: 2768-74.
57. Ducoulombier D, Roque-Afonso AM, Di Liberto G, Penin F, Kara R, Richard Y, et al. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 2004; 39: 817-25.
58. Sansonno D, Tucci FA, Lauletta G, De Re V, Montrone M, Troiani L, et al. Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia. Clin Immunol 2007; 147: 241-8.
59. Bartosch B, Dubuisson, J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-42.
60. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6.
61. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-71.
62. Germi R, Cran JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, et al. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 2002; 68: 206-15.
63. Koutsoudakis G, Herrmann E, Kallis S, Bartenschlager R, Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol 2007; 81: 588-98.
64. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005; 41: 265-74.
65. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-25.
66. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003; 278: 41624-30.
67. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-5.
68. Meertens L, Bertaux C, Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol 2006; 80: 11571-8.
69. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100: 7271-6.
70. Helle F, Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci 2008; 65: 100-12.
71. Yamada E, Montoya M, Schuettler CG, Hickling TP, Tarr AW, Vitelli A, et al. Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. J Gen Virol 2005; 86: 2507-12.
72. Damian RT. Molecular mimicry in biological adaptation. Science 1965; 147: 824.
73. Oldstone MB. Molecular mimicry and autoinumme disease. Cell 1987; 50: 819-20.
74. Bogdanos DP, Eboudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: Virtuous intentions, malign consequences. Liver 2001; 21: 225-32.
75. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2:85-95.
76. Muratori, Bogdanos DP, Muratori P, Lenzi M, Granito A, Ma Y, et al. Susceptibility to thyroid disorders in hepatitis C. Clin Gastroenterol Hepatol 2005; 3: 595-603.
77. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370-8.
78. Bogdanos DP, Lenzi M, Okamoto M, Rigopoulou EI, Muratori P, Ma Y, et al. Multiple virul/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 2004; 17: 83-92.
79. Marceau G, Lapierre P, Beland K, Soudeyns H, Alvarez F. LKM1 autoantibodies in chronic hepatitis C infection: A case of molecular mimicry? Hepatology 2005; 42: 675-82.
80. Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, et al. Cytachrome P4502D6(193-212): A new inummodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Inummol 2003; 170:1481-9.
81. Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006; 130: 868-82.
82. Sugimura T, Obermayer-Straub P, Kayser A. Braun S, Loges S, Alex B, et al. A major CYP2D6 autoopitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens. Autoimmunity 2002; 35: 501-13.
83. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmume liver disease. Hepatology 2002; 35: 658-64.
84. Gregorio GV, Choudhuri K, Ma Y, Pensati P, Iorio R, Grant P, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 2003; 133: 404-13.
85. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: Specific detection of negative-strand viral RNA in various tissues. Hepatology 1998; 28: 1398-401.
86. Prummel W, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003; 13: 547-51.
87. Yue SJ, Enomoto T, Matsumoto Y, Kawai K, Volpe R. Thyrocyte class I and class II upregulation is a secondary phenomenon and does not contribute to the pathogenesis of autoimmune thyroid disease. Thyroid 1998; 8: 755-63.
88. Castelruiz Y, Larrea E, Boya P, Civeira MP, Prieto J. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. Hepatology 1999; 29: 1900-4.
89. De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 2000; 96: 3578-84.
90. Ferri S, Dal Pero F, Bortoletto G, Bianchi FB, Lenzi M, Alberti A, et al. Detailed analysis of the E2-IgM complex in hepatitis C-related type II mixed cryoglobulinaemia. J Viral Hepat 2006; 13: 166-76.
91. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non- Hodgkin lymphoma binds the vital E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001; 98: 3745-9.
92. Newkirk MM. Rheumatoid factors: Host resistance or autoimmunity? Clin Immunol 2002; 104: 1-13.
93. Do Re V, Sansonno D, Simula MP, Caggiari L, Gasparotto D, Fabris M, et al. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia 2006; 20: 1145-54.
94. Stroffolini T, Colloredo G, Gaeta GB, Sonzogni A, Angeletti S, Marignani M, et al. Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey. J Viral Hepat 2004; 11: 257-62.
95. Hsieh MY, Dai CY, Lee LP, Huang JF, Tsai WC, Hou NJ, et al. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol 2008; 61: 333-7.
96. Muratori P, Muratori L, Verucchi G, Attard L, Bianchi FB, Lenzi M. Non-organ-specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment. Clin Infect Dis 2003; 37: 1320-6.
97. Wasmuth HE, Stolte C, Geier A, Dietrich CG, Gartung C, Lorenzen J, et al. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004; 4: 4.
98. Muratori P, Muratori L, Guidi K Granito A, Susca K Lenzi M, et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005; 40: 501-7.
99. Giostra F, Manzin A, Lenzi K Francesconi R, Solibrosi L, Manotti P, et al. Low hepatitis C viremia levels in patients with anti-liver/ kidney microsomal antibody type 1 positive chronic hepatitis. J Hepatol 1996; 25: 433-8.
100. Muratori L, Parola M, Ripalti A, Robino G, Muratori P, Bellomo G, et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 2000; 46: 553-61.
101. Bortolotti F, Vajro P, Balli F, Giacchino R, Crivellaro C, Barbera C, et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25: 614-20.
102. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 1770-7.
103. Iijima Y, Kato T, Miyakawa H, Ogino K Mizuno K Sugihara K, et al. Effect of interferon therapy on Japanese chronic hepatitis C virus patients with anti-liver/kidney microsome autoantibody type 1. J Gastroenterol Hepatol 2001; 16: 782-8.
104. Muratori L, Lenzi M, Cataleta M, Giostra F, Cassani F, Ballardini G, et al. Interferon therapy in fiver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21: 199-203.
105. Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995; 22: 1374-8.
106. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117: 10-3.
107. Loviselli A, Oppo A, Velluzzi F, Atzeni F, Mastinu GL, Farci P. et al. Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection m the general population: results of a community-based study in north-western Sardinia. J Endocrinol Invest 1999; 22: 660-5.
108. Deutsch K Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, et al. Thyroid abnormalities in chronic vital hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26: 206-10
109. Meltzer K Franklin EC, Elias K, McCloskey RT, Cooper N. Cryoglobulinemia-a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40: 837-56.
110. Saadoun D, Asselah T, Resche-Rigon K Charlotte F, Bedossa P, Valla D, et al. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology 2006; 43: 1337-45.
111. Kayali Z, Buckwold VE, Zimmerman B. Schmidt WN. Hepatitis C, cryoglobulinemia, and cirrhosis: A meta-analysis, Hepatology 2002; 36: 978-85.
112. Vigano K Lampertico P, Rumi MG, Folli C, Maggioni L, Morabito A, et al. Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients. Gastroenterology 2007; 133: 835-42.
113. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryo-globulinemia vasculitis: A long-term followup study. Arthritis Rheum 2006; 54: 3696-706.
114. Briani C, Chemello L, Zara G, Ermani K Bernardinello E, Ruggero S, et al. Peripheral neurotoxicity of pegylated interferon alpha: A prospective study in patients with HCV. Neurology 2006; 67: 781-5.
115. De Blasi T, Aguilar MD, Cariti G, Maiello A, Do Rosa FG, Di Perri G. Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b. Infection 2007; Oct 25 [Epub ahead of print].
116. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39: 2-17.
117. Camateros P, Moisan J, Henault J, Do Sanctis J, Skamene E, Radzioch D. Toll-like receptors, cytokines; and the immunotherapeutics of asthma. Curr Pharm Des 2006; 12(19): 2365-74.
118. Moller S, Zettl M Serrano-Fernandez P, Goertsches R. Comparative genomics for the investigation of autoinimune diseases. Curr Pharm Des 2006; 12(29): 3707-22.
119. Muller-Hilke B, Mitchison NA. The role of HLA promoters in autoimmunity. Curr Pharm Des 2006; 12(29): 3743-52.